Day: January 4, 2024

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer. Dr. Quartel brings more than 20 years of experience in the international pharmaceutical industry with senior roles in clinical development, pharmacovigilance and medical affairs. “It is an honor to welcome Dr. Quartel to our team during an exciting period of growth for Zevra after our recent acquisition of Acer Therapeutics and the expansion of our rare disease portfolio,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra. “His extensive expertise in overseeing clinical development and leading the commercialization of multiple rare disease assets will play a pivotal...

Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials. The six- to eight-week non-GLP study includes single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study....

LeapChargerRedesigned PackagingCARSON CITY, NV, Jan. 04, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – LeapCharger Corporation (OTC: LCCN) (“LeapCharger” or the “Company”), an electric vehicle (EV) charging company with disruptive and innovative technology providing eco-friendly and sustainable solutions, is pleased to announce its foray into the retail sector. The Company intends to revolutionize the industry by making its line of home EV charging solutions available for purchase on the shelves of supermarkets in Dubai. LeapCharger’s recently completed new line of home EV charging solutions is designed to meet the burgeoning demand for accessible and efficient charging options. With a commitment to sustainable mobility, the company aims to empower EV owners by bringing the charging experience directly...

Record Numbers Reported Both in December 2023 and Q4 of 2023 JOHNS CREEK, Ga., Jan. 04, 2024 (GLOBE NEWSWIRE) — Ebix, Inc. (OTC: EBIXQ), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare, and e-learning industries, announced today that its Annuity Exchange AN4 has reported record volumes in the last quarter of 2023, besides reporting a record performance for the full year of 2023. Ebix’s AN4 Annuity exchange is an integral key part of Ebix’s North America Life & Annuity Division, that includes other assets like LifeSpeed, the industry leading Order Entry platform; WinFlex, a market-leading multi-carrier illustration tool used by over 35 carriers and more than 275,000 users; TPP (The Policy Processor), an industry leading underwriting platform; and SmartOffice,...

Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of a case report in Heliyon, Cell Press’s peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/S2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy. As is often the case with such patients, tolerance developed to the standard anti-epileptic treatments, rendering them ineffective, and the patient required a craniotomy in order to remove the brain tissue responsible for the seizure generation. One year after surgery, the patient remains seizure free, but remains...

Figure 1Magnetic resonance imaging (MRI) of the orbital tumor. The top left MRI image shows the tumor in the right orbit behind the eye with the eye not being visible pre-treatment. After treatment with the Bria-IMT™ regimen, the eye becomes visible (top right image) as it has regained its normal position. In the lower images, the dashed line represents normal margin of eye position with resolution of proptosis post treatment (small arrows) with the Bria-IMT™ regimen. Reduction in tumor is represented by large arrows.Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including antibody-drug conjugate therapy and remains...

SKRE Becomes only ETF that shorts regional banks GREENWICH, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) — via IBN — The 2x Inverse Regional Bank ETF, (NASDAQ: SKRE), will start trading today at the Nasdaq Exchange. The fund uses swaps to gain inverse daily 2x exposure to the SPDR S&P Regional Banking ETF (Symbol: KRE). Matthew Tuttle, CEO of Tuttle Capital, said in a news release that SKRE is a trading tool that has long been needed in the marketplace. “This year saw a number of regional banks go under” Tuttle said. “These guys are not too big to fail, when they start to have problems, things can spiral quickly, and nobody is going to bail them out.” Tuttle is concerned that the higher for longer interest rate stance by the Fed and potential issues in commercial real estate could mean that we see more regional banks go under...

DURANGO, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMC”, or “Rocky Mountain Chocolate”), an international franchisor and producer of premium chocolates and other confectionery products, including gourmet caramel apples, will host a conference call on Thursday, January 11, 2024 at 8:30 a.m. Eastern time to discuss its fiscal third quarter 2024 results. The Company’s results will be reported in a press release prior to the call. The RMCF management team will host the conference call, followed by a question-and-answer period. Attendees are invited to submit questions ahead of the call by emailing the Company’s investor relations team at RMCF@elevate-ir.com. The conference call details are as follows: Date: Thursday, January 11, 2024Time: 8:30 a.m. Eastern timeDial-in...

Highlights include record revenue so far this year, asset sale of $4 million, strengthened balance sheet, elimination of convertible debt, and a strong pipeline for 2024 SAN ANTONIO, Jan. 04, 2024 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today its 2023 highlights. The Company also participated in an investor podcast to discuss 2023 achievements and 2024 goals, which can be heard here: https://www.youtube.com/watch?v=64_UULOJ3zM 2023 HighlightsRevenue was over $1.7 million for the first nine months of 2023, exceeding revenue for the first nine-month period of any prior year, even without the contribution of any revenue from our previously owned C-Bond nanoShield product, which we sold in the second quarter...